Desvenlafaxine Tablet, Extended Release
Product Images NDC 50090-5274

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-5274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

This is a drug study that evaluates the effect of renal and hepatic impairment as well as gender and age on the concentration of a drug, measured through its Cmax and AUC. The results provide the geometric mean ratios with confidence intervals for each group compared to a reference group. The drug may need to be adjusted in patients with severe renal or hepatic impairment, as the Cmax and AUC are significantly higher than in the reference group. Females may require a slightly lower dose than males. Age appears to have a limited effect on the drug's concentration. The study excluded non-English characters.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

This appears to be a table displaying changes in CYP3A4 activity due to the presence of the drug ketoconazole as compared to a reference. The values represent geometric mean ratios for maximum concentration (Cmax) and area under the curve (AUC) with 30% confidence intervals. Without additional context, it is unclear what the units of measurement are.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

The text provides a graph showing the estimated proportion of patients with relapse over time (in days) from randomization, comparing Desvenlafaxine Extended-Release Tablets 50mg to Placebo. The estimate of the proportion of patients with relapse is 10%. The graph shows that Desvenlafaxine Extended-Release Tablets 50mg may be more effective in preventing relapse compared to placebo.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

The text appears to be a graph showing the estimated proportion of patients with relapse over time for Desvenlafaxine Extended-Release Tablets compared to a Placebo. The X-axis represents the time to relapse in days from randomization, while the Y-axis represents the estimated proportion of patients with relapse in percentage. However, as there is no clear indication of what the values on the X and Y axes signify or what the context of the data is, the description may not be entirely accurate.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

FDA Label Image

Label Image (Lbl500905274)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.